• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pyxis Oncology, Inc. - Common Stock (NQ: PYXS )

    1.560 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pyxis Oncology, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
    Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges. 
    Via Benzinga
    Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
    From Pyxis Oncology
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
    Via Benzinga
    Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
    Via Benzinga
    Exposures Fossil Fuels
    Pyxis Oncology: Q4 Earnings Insights
    Via Benzinga
    Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
    Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer. 
    Via Benzinga
    Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
    Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and a $13 price target, with upcoming clinical trial results. 
    Via Benzinga
    Pyxis Oncology to Participate in Two Upcoming Investor Conferences
    From Pyxis Oncology
    Via GlobeNewswire
    PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024
    PYXS stock results show that Pyxis Oncology missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
    From Pyxis Oncology
    Via GlobeNewswire
    PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024
    PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
    From Pyxis Oncology
    Via GlobeNewswire
    Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
    Via Benzinga
    Exposures Glyphosate
    Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
    U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pyxis Oncology
    Via GlobeNewswire
    3 Biotech Stocks to Buy on the Dip: March 2024
    Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
    Via InvestorPlace
    Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
    From Pyxis Oncology
    Via GlobeNewswire
    Why FedEx Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
    Shares of FedEx Corporation (NYSE: FDX) rose sharply in today’s pre-market trading after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion 
    Via Benzinga
    PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023
    PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.